Leigh Marcus

Leigh Marcus

Auto-generated profile, based on publicly available information

Leigh Marcus

Office of Scientific Investigations (OSI), Office of Compliance Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TPTimil H. Patel
Timil H. Patel
LMLeigh Marcus
Leigh Marcus
MHM. Naomi Horiba
M. Naomi Horiba
MDMartha Donoghue
Martha Donoghue
SCSomak Chatterjee
Somak Chatterjee
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Approval was based on FIGHT-202 (NCT02924376), a multicenter open-label single-arm trial. Efficacy was based on 107 patients with locally advanced unresectable or metastatic cholangiocarcinoma whose disease had progressed on or after at least one prior therapy and had an FGFR2 gene fusion or rearrangement. Patients received pemigatinib, 13.5 mg orally, once daily for 14 consecutive days, followed by 7 days off therapy. Safety was based on a total of 466 patients, 146 of whom had cholangiocarcinoma and received the recommended dose. Efficacy endpoints were overall response rate (ORR) and duration of response (DOR) determined by an independent review committee using RECIST 1.1. ORR was 36% (95% confidence interval: 27–45). Median DOR was 9.1 months. The most common adverse reactions were hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin. Ocular toxicity and hyperphosphatemia are important risks of pemigatinib. The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles. FDA also approved the FoundationOne CDX (Foundation Medicine, Inc.) as a companion diagnostic for patient selection.

3 January 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
SASrivandana Akshintala
Srivandana Akshintala
LMLeigh Marcus
Leigh Marcus
KWKatherine E. Warren
Katherine E. Warren
RMRobert F. Murphy
Robert F. Murphy
TSTristan M. Sissung
Tristan M. Sissung
BWBrigitte C. Widemann
Brigitte C. Widemann
Background Based on pre‐clinical and clinical activity in adult refractory tumors, and absence of significant neuro‐, nephro‐, or oto‐toxicity, we conducted a pediatric phase 1 trial to determine the toxicities, maximum tolerated dose (MTD), and pharmacokinetics of satraplatin, an oral platinum analogue, in children and young adults with refractory solid tumors. Procedure Satraplatin was administered orally once daily on days 1–5 of a 28‐day cycle at dose level (DL) 1 (60 mg/m2/dose), and DL2 (80 mg/m2/dose). Toxicities, responses, satraplatin pharmacokinetics, and pharmacogenomic expression of specific DNA repair genes were evaluated. Results Nine patients received 1–15 cycles (median = 2). The MTD was exceeded at DL2 with delayed prolonged myelosuppression as dose‐limiting toxicity (DLT) in 2/4 patients. At DL1, 0/5 patients had DLTs. Common non‐DLTs included myelosuppression, gastrointestinal toxicities, fatigue, headache, liver enzyme elevation, and electrolyte abnormalities. No significant neuro‐, nephro‐, or oto‐toxicity was observed. No objective responses were observed but 2 patients experienced prolonged disease stabilization (­­­6–15 cycles). Satraplatin exposure (day 1 plasma ultrafiltrate area under the curve) was similar at DL1 and DL2. A strong correlation between estimated creatinine clearance and satraplatin pharmacokinetic parameters (clearance, area under the curve, and peak concentration) was observed. Conclusions The MTD of oral satraplatin in children with solid tumors was 60 mg/m2/dose daily ×5 days every 28 days, which is lower than the adult recommended dose of 80–120 mg/m2/dose. The toxicity profile was similar to adults and delayed myelosuppression was the DLT. No significant neuro‐, nephro‐ or oto‐toxicities were observed. Pediatr Blood Cancer 2015;62:603–610.

5 November 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CGCheryl Grandinetti
Cheryl Grandinetti
MBMandy Budwal‐Jagait
Mandy Budwal‐Jagait
HAHocine Abid
Hocine Abid
EGEmily Gebbia
Emily Gebbia
EBElena Boley
Elena Boley
KAKassa Ayalew
Kassa Ayalew